Woebot represents a fundamentally different category of tool than anything else on our specialty lists. It's not a clinical decision support platform for psychiatrists — it's a patient-facing digital therapeutic that delivers evidence-based psychotherapy techniques through an AI chatbot. The distinction matters, and it's why Woebot scored lower than the clinician-facing tools in our overall evaluation criteria while still earning a place on our psychiatry specialty list for its clinical relevance.
Developed at Stanford by clinical psychologist Dr. Alison Darcy, Woebot uses natural language processing to guide users through CBT-based exercises, mood tracking, and therapeutic conversations. The chatbot doesn't diagnose or prescribe — it teaches coping skills, challenges cognitive distortions, and provides structured psychological support between therapy sessions. A 2017 randomized controlled trial published in JMIR Mental Health showed that college students using Woebot for two weeks experienced significant reductions in depression symptoms compared to a control group.
Woebot received FDA Breakthrough Device Designation for its prescription digital therapeutic targeting major depressive disorder in adolescents ages 13-17 — a population with severe access barriers to traditional psychiatric care. The company has shifted its business model toward enterprise partnerships with health systems and payers, moving away from direct-to-consumer access.
For psychiatrists, Woebot is relevant as an adjunct to treatment rather than a clinical decision support tool. It can extend therapeutic reach between appointments, provide structured CBT exercises for patients who can't access regular therapy, and support the 31,000-psychiatrist shortage in the US by scaling evidence-based interventions. This review evaluates Woebot exclusively for its relevance to psychiatry and behavioral health. As a patient-facing digital therapeutic rather than a clinician CDS tool, it was not included in our overall rankings.